Combined Q-switched Nd:YAG Laser and Platelet Rich Plasma Versus Q- Switched Nd:YAG Laser Alone in Melasma
Launched by CAIRO UNIVERSITY · Feb 18, 2021
Trial Information
Current as of September 03, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with bilateral nearly symmetric melasma on the face.
- Exclusion Criteria:
- • Patients receiving systemic or topical or laser treatment relevant to melasma within three months before enrollment into the study.
- • Use of oral or injectable contraceptives or hormone replacement therapy during treatment or 12 months before
- • Patients active skin infections and active HSV
- • History of hypertrophic scars or keloids.
- • Patients with hypercoagulable state or bleeding diatheses
- • Pregnant and lactating females.
- • History of liver diseases
- • Intake of systemic chemotherapy, corticosteroids, antiplatelets or anticoagulants
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials